Trials / Not Yet Recruiting
Not Yet RecruitingNCT06589830
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Suzhou Teligene Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TL938 Capsules | Oral administration |
| DRUG | Trastuzumab | Intravenous (IV) infusion |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
- First posted
- 2024-09-19
- Last updated
- 2025-05-15
Source: ClinicalTrials.gov record NCT06589830. Inclusion in this directory is not an endorsement.